You are here: Home: Audio Program Guide: BCU 6 | 2006 Audio: BCU 6 | 2006
 
  Go to interview with Marc E Lippman, MD
Go to interview with C Kent Osborne, MD
Go to interview with I Craig Henderson, MD
Go to interview with Charles E Geyer Jr, MD
Go to interview with Frank A Vicini, MD
Go to the case discussion of MBCC Tumor Panel Discussion on Systemic Therapy of Metastatic Disease


 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Marc E Lippman, MD
John G Searle Professor and
Chair, Department of Internal
Medicine, University of Michigan
Ann Arbor, Michigan		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Development of therapies targeting apoptotic pathways
Track 3 Identification of predictors of response to chemotherapy and targeted therapies
Track 4 Classification of breast cancer based on molecular profile
Track 5 Utility of the Oncotype DX™ assay and other discriminant models in breast cancer
Track 6 Effectiveness of chemotherapy based on hormone receptor status

Track 7 Topoisomerase II-alpha (TOPO II) gene amplification as a predictor of response to anthracycline-containing chemotherapy in BCIRG 006
Track 8 Effectiveness of trastuzumab in patients coamplifying HER2 and cMYC
Track 9 Potential mechanisms of action of bevacizumab
Track 10 Identification and therapeutic targeting of mutations in cancer
Track 11 Barriers to the continued development of cancer therapeutics and technologies
     
C Kent Osborne, MD
Director, Cancer Center
Professor of Medicine and
Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Biologic rationale for the use of anti-HER2 therapy to overcome resistance to endocrine therapy
Track 3 Potential restoration of hormone sensitivity in patients treated with trastuzumab
Track 4 Reliability and accuracy of hormone receptor and HER2 assays
Track 5 ER, PR and HER2 status and response to endocrine therapy
Track 6 Optimal long-term adjuvant hormonal therapy

Track 7 Potential advantages and clinical utility of the Oncotype DX assay
Track 8 Hormone receptor status and response to chemotherapy
Track 9 Optimal dose and schedule of fulvestrant
Track 10 Nanoparticle albumin-bound (nab) paclitaxel
     
I Craig Henderson, MD
Adjunct Professor of Medicine
University of California, San Francisco
San Francisco, California		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Historical perspective on the evolution of therapeutic approaches in breast cancer
Track 3 TOPO II amplification as a predictor of response to anthracycline-based chemotherapy
Track 4 Enhanced delivery of chemotherapy to tumors with nab paclitaxel
Track 5 Administration and toxicity advantages of nab paclitaxel
Track 6 Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) overexpression on delivery of nab paclitaxel

Track 7 Potential mechanism of action of bevacizumab
Track 8 ECOG-E2100 and clinical trial results with bevacizumab in other solid tumors
Track 9 Historical perspective on the development of novel therapeutics
Track 10 Biologic rationale for the effectiveness of dose-dense scheduling of chemotherapy
Track 11 Use of dose-dense AC in patients with node-negative disease
     
Charles E Geyer Jr, MD
Director of Medical Affairs
National Surgical Adjuvant Breast
and Bowel Project
Director of Breast Medical Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Phase III randomized trial of capecitabine with or without lapatinib in women with previously treated, HER2-positive, metastatic breast cancer
Track 3 Mechanism of action of lapatinib
Track 4 Results of the Phase III randomized trial of capecitabine with or without lapatinib
Track 5 Clinical use of lapatinib
Track 6 Trials evaluating adjuvant or neoadjuvant lapatinib

Track 7 Planned NSABP neoadjuvant trial in women with HER2-positive disease
Track 8 Planned NSABP adjuvant trial in women with HER2-positive disease
Track 9 Clinical use of adjuvant trastuzumab in older women or women with cardiac risk factors
Track 10 Trial of trastuzumab/docetaxel with or without carboplatin in women with metastatic disease
Track 11 Cardiac monitoring of patients treated with trastuzumab
Track 12 NSABP-B-40: Neoadjuvant bevacizumab trial
Track 13 NSABP-B-38: Adjuvant TAC versus dose-dense chemotherapy
Track 14 Duration of adjuvant aromatase inhibitor therapy
Track 15 Clinical use of the Oncotype DX assay
     
Frank A Vicini, MD
Chief of Oncology Services
Oncology Services Administration
William Beaumont Hospital
Royal Oak, Michigan		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 NSABP-B-39: A randomized study of whole breast versus partial breast irradiation therapy
Track 3 Use of partial breast irradiation techniques
Track 4 Selection of partial breast irradiation techniques
Track 5 Preliminary outcome data from the MammoSite® Breast Brachytherapy Registry Trial
Track 6 Use of partial breast irradiation therapy for DCIS

Track 7 Identification of patients who do not need radiation therapy
Track 8 Trends in use of breast-conserving surgery
Track 9 Intensity-modulated radiation therapy in breast cancer
     
  MBCC Tumor Panel Discussion on Systemic Therapy of Metastatic Disease
  
  Click here to download the entire case discussion  
Track 1 Introduction
Track 2 Changes in the treatment of patients with metastatic breast cancer
Track 3 Challenges in the development of new targeted therapies
Track 4 Tumor markers in breast cancer
Track 5 Case 1: A 55-year-old woman with ER-negative, PR-negative, HER2-negative metastatic breast cancer that is rapidly progressing
Track 6 Treatment options for a woman with ER-negative, PR-negative, HER2-negative metastatic breast cancer

Track 7 ECOG-E2100: Paclitaxel with or without bevacizumab
Track 8 Combining bevacizumab with chemotherapy
Track 9 Clinical applicability of the results from ECOG-E2100
Track 10 Clinical use of platinum agents in women with ER-negative, PR-negative, HER2-negative disease
Track 11 Clinical use of bevacizumab in the metastatic setting
Track 12 Randomized Phase II trial of metronomic chemotherapy with or without bevacizumab
Track 13 Clinical trials of adjuvant and neoadjuvant bevacizumab
Track 14 Case 2: A 57-year-old postmenopausal woman with ER-positive, PR-positive, HER2-negative breast cancer who relapses while receiving adjuvant anastrozole
Track 15 Clinical use of loading doses of fulvestrant
Track 16 Clinical trials evaluating an aromatase inhibitor in combination with fulvestrant
Track 17 Hormonal therapy selection in the postmenopausal patient with metastatic disease
Track 18 Patients’ preferences for oral versus injectable therapy
Track 19 Trial of extended adjuvant therapy with fulvestrant